DEMAND

A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by ondemand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients

II

interventionell

National

Atezolizumab (Tecentriq®), Bevacizumab (Avastin®)

Status: In Rekrutierung

Zeitraum

2020

2023

Zentren

15

15

Zentren gesucht

Patienten

106

34

11.04.2022

Klinische Settings

1st line

palliativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

Klinikum der Universität München

Identifier

AIO-HEP-0418

AIO-HEP-0418

2019-002430-36

Kontakt

Leitung

Prof. Dr. med. Enrico De Toni

Ansprechpartner*in

Prof. Dr. Enrico De Toni / Dr. Najib Ben Khaled
E-Mail enrico.detoni@med.uni-muenchen.de